MD‐Logic overnight type 1 diabetes control in home settings: Amulticentre, multinational, single blind randomized trial
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Aims: To evaluate the safety, efficacy and need for remote monitoring of the MD‐L ogic closed‐loop system during short‐term overnight use at home. Methods: Seventy‐five patients (38 male; aged 10‐54 years; average A1c, 7.8% ± 0.7%, 61.8 ± 7.2 mmol/mol) were enrolled from 3 clinical sites. Patients were randomly assigned to participate in 2 overnight crossover periods, each including 4 consecutive nights, 1 under closed‐loop control and 1 under sensor‐augmented pump ( SAP ) therapy in the patient's home. Both study arms were supervised using a remote‐monitoring system in a blinded manner. Primary endpoints were time spent with glucose levels below 70 mg/d L and percentage of nights in which mean overnight glucose levels were within 90 to 140 mg/d L . Results: The median [interquartile range] percentage of time spent in hypoglycaemia was significantly lower on nights when MD‐L ogic was used, compared to SAP therapy (2.07 [0, 4.78] and 2.6 [0, 10.34], respectively; P = .004) and the percentage of individual nights with a mean overnight glucose level in target was significantly greater (75 [42, 75] and 50 [25,75], respectively; P = .008). The time spent in target range was increased by a median of 28% ( P = .001), with the same amount of insulin (10.69 [7.28, 13.94] and 10.41[6.9, 14.07], respectively; P = .087). The remote monitoring triggered calls for hypoglycaemia at twice the rate during SAP therapy compared to closed‐loop control (62 and 29, respectively; P = .002). Conclusions: The MD‐L ogic system demonstrated a safe and efficient profile during overnight use by children, adolescents and adults with type 1 diabetes and, therefore, provides an effective means of mitigating the risk of nocturnal hypoglycaemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Home Use of an Artificial Beta Cell in Type 1 Diabetes
Thabit, H., Tauschmann, M., Allen, J. M., Leelarathna, L., Hartnell, S., Wilinska, M. E., Acerini, C. L., Dellweg, S., Benesch, C., Heinemann, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509351 · Cited by 450 · cited 2×
“In fact, the Cambridge group have already published successful trials in adults and adolescents in unsupervised home studies.(29,30) Integration of the system into the daily life of patients was simple.”
BackgroundMethodKovatchev, B., Cobelli, C., Renard, E., Anderson, S., Breton, M., Patek, S., Clarke, W., Bruttomesso, D., Maran, A., Costa, S., et al. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400611 · Cited by 200
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2010) · Diabetes Care · doi:10.2337/dc09-2081 · Cited by 180
Multinational Home Use of Closed-Loop Control Is Safe and Effective
Anderson, S. M., Raghinaru, D., Pinsker, J. E., Boscari, F., Renard, E., Buckingham, B. A., Nimri, R., Doyle, F. J., Brown, S. A., Keith-Hynes, P., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2468 · Cited by 120 · cited 1×
“reported on 2 weeks of overnight home use, followed by 2 weeks of day and night home use under conditions of remote monitoring.(36) The results were compared to 2 weeks baseline SAP therapy.”
ResultSelf-citation
Cited by
Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes
Rodbard, D. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0035 · Cited by 458
Bekiari, E., Kitsios, K., Thabit, H., Tauschmann, M., Athanasiadou, E., Karagiannis, T., Haidich, A.-B., Hovorka, R., & Tsapas, A. (2018) · BMJ · doi:10.1136/bmj.k1310 · Cited by 437
Artificial intelligence in diabetes management: Advancements, opportunities, and challenges
Guan, Z., Li, H., Liu, R., Cai, C., Liu, Y., Li, J., Wang, X., Huang, S., Wu, L., Liu, D., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101213 · Cited by 412
“88 Optimal strategy for anti-diabetic drug therapy Clinicians provide therapeutic advice beyond insulin dosing guidance (particularly T2D), as diabetes is often associated with multiple comorbidities, leading to complex guidelines for personalized treatment, with gaps often present in which no…”
BackgroundArtificial Intelligence Methodologies and Their Application to Diabetes
Rigla, M., García-Sáez, G., Pons, B., & Hernando, M. E. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817710475 · Cited by 131
Hu, Y., Wen, X., Wang, F., Yang, D., Liu, S., Li, P., & Xu, J. (2019) · Journal of Telemedicine and Telecare · doi:10.1177/1357633x18776823 · Cited by 57
Metadata
- Authors
- Nimri, R., Bratina, N., Kordonouri, O., Avbelj Stefanija, M., Fath, M., Biester, T., Muller, I., Atlas, E., Miller, S., Fogel, A., Phillip, M., Danne, T., & Battelino, T.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-01-19
- Volume
- 19
- Issue
- 4
- Pages
- 553-561
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2564924912
- Cited by
- 42
- References
- 6
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.